“We are pleased with our preliminary Q4 2023 revenue which exceeded our expectations and demonstrates that our commercial realignment and execution are delivering stronger and more consistent growth,” said Kevin Thornal, CEO. “Also, we are excited to enter the fast-growing sacroiliac joint space through our recent acquisition of Vyrsa Technologies, which allows us to leverage one of our greatest assets – our commercial team. As we look ahead, we remain focused on delivering on our three key pillars of commercial execution, market penetration and profit progress.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVRO:
- Nevro price target raised to $23 from $22 at Truist
- Salesforce upgraded, Chipotle downgraded: Wall Street’s top analyst calls
- Nevro downgraded to Hold at Canaccord on increased competition
- Nevro downgraded to Hold from Buy at Canaccord
- Citi entering 2024 ‘cautiously optimistic’ on U.S. MedTech companies
